Table 3.
Responses to treatment by tumor type
| Responses and histology | Patient No. | Dose level | Total No. of cycles |
|---|---|---|---|
| Partial response | |||
| BRCA2+ ovarian cancer | 12 | 4 | 32 |
| BRCA2+ ovarian cancer | 4 | 2 | 20 |
| BRCA2+ ovarian cancer | 23 | 7 | 17 |
| BRCA2+ ovarian cancer | 34 | 8 | 10 |
| BRCA2+ ovarian cancer | 5 | 2 | 8 |
| BRCA2+ triple-negative breast cancer | 20 | 7 | 8 |
| Breast cancer | 15 | 5 | 4 |
| Prolonged stable diseasea | |||
| SLL/CLL | 1 | 1-7 | 42 |
| BRCA2+ breast cancer (male) | 14 | 5 | 15 |
| Urothelial cancer | 32 | 7 | 17 |
| BRCA2+ ovarian cancer | 25 | 7 | 11 |
| Urothelial cancer | 31 | 7 | 8 |
| BRCA+ breast cancer | 29 | 7 | 6 |
a
Stable disease for at least six cycles.
Abbreviation: SLL/CLL, small lymphocytic lymphoma/chronic lymphoid leukemia.